Abstract
Cyclophosphamide, a widely used antineoplastic agent, is renowned for its efficacy in treating various cancers. However, its therapeutic potential is often accompanied by a spectrum of adverse drug reactions (ADRs). This pharmacovigilance project aims to systematically monitor and analyze the safety profile of cyclophosphamide, focusing on the identification, reporting, and prevention of ADRs. By implementing a robust pharmacovigilance strategy, this project seeks to: Enhance Patient Safety: Early detection and reporting of ADRs can lead to timely interventions, reducing the severity and potential long-term consequences of adverse events. Optimize Therapeutic Use: A comprehensive understanding of the risk-benefit profile of cyclophosphamide can guide clinicians in making informed decisions about its appropriate use and dosage regimens. Through a combination of literature review, case report analysis, and spontaneous reporting, this project will provide valuable insights into the real-world safety profile of cyclophosphamide. The findings of this study will be disseminated to healthcare professionals, regulatory authorities, and patients to promote the safe and effective use of this important therapeutic agent.
Keywords
1. Pharmacovigilance 2. Cyclophosphamide 3. Alkylating agents 4. Myelosuppresion 5. Adverse Drug Reactions 6. Hemorrhagic Cystitis
How to Cite:
Ms. Sayli Ravindra Dabhade ,Mr. Abhay Kishor Jaitmal, Ms. Vaishnavi Raghunath Jadhav , ADR REPORTING OF CYCLOPHOSPHAMIDE , Volume 10 , Issue 4, april 2025, EPRA International Journal of Research & Development (IJRD),